Tislelizumab combined with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer can provide patients with “encouraging antitumor activity,” investigators concluded based on a small retrospective pilot study. The study was published in BMC Urology.
The study included 31 patients, of whom 14 received tislelizumab plus gemcitabine/cisplatin and 17 received only gemcitabine/cisplatin. All patients underwent bladder cytoreductive surgery and were treated for 4 cycles of 21 days each until disease progression or intolerable treatment-related adverse events (TRAEs). The median survival follow-up duration was 54.3 weeks for the tislelizumab arm and and 52.1 weeks for the gemcitabine/cisplatin arm.
At a cutoff date of March 25, 2022, the median progression-free survival was 36 weeks in the tislelizumab group and 29 weeks in the gemcitabine/cisplatin group. The tislelizumab arm had a significant 85% decreased risk for disease progression compared with gemcitabine/cisplatin arm.
The median overall survival was 48 weeks for the gemcitabine/cisplatin group and not yet mature for the tislelizumab group, which experienced a significant 74% decreased risk of death.
Further, the tislelizumab group had an improved disease control rate compared with the gemcitabine/cisplatin group (71.4% vs 65%), as well as an improved clinical benefit rate (64.3% vs 52.9%).
The tislelizumab group had more grade 3 or higher TRAEs than the gemcitabine/cisplatin group, but the difference was not statistically significant (35.7% vs 23.5%). Tislelizumab plus chemotherapy was generally well tolerated, according to the researchers.
“To our knowledge, this was the first retrospective report of [gemcitabine/cisplatin] chemotherapy as a single agent or in combination with tislelizumab in patients with locally advanced or metastatic bladder cancer as the first line therapy,” the researchers wrote.
Ren X, Tian Y, Wang Z, et al. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: A retrospective study. BMC Urol. Published online August 20, 2022. doi:10.1186/s12894-022-01083-8
This article originally appeared on Renal and Urology News